Therapeutic vaccination for the treatment of mucosotropic human papillomavirus-associated disease

Expert Opinion on Biological Therapy
N Randall Chu

Abstract

There is a high prevalence of diseases caused by human papillomavirus (HPV) infection. Unfortunately, current treatments are inadequate. However, because there is evidence to support a role for the immune system in host defence against this virus, an immunotherapeutic approach is warranted. The existing immunotherapies are not completely effective, nor are they durable. In addition, natural history studies associated with spontaneous regression have provided little guidance to the design of successful interventions. This state of knowledge has encouraged efforts towards the development of novel immunotherapeutic strategies. Successful preclinical studies of therapeutic vaccine candidates have led to clinical studies for a variety of HPV-associated indications, such as anogenital warts and cervical and anal intraepithelial neoplasia. Immunisation approaches such as adjuvanted peptides, virus-like particles and fusion constructs are discussed. Specifically, chimaeric molecules comprised of mycobacterial heat-shock proteins (Hsps) and HPV16 E7 appear promising.

References

Jan 1, 1991·Proceedings of the National Academy of Sciences of the United States of America·L P ChenK E Hellström
Jan 1, 1983·Proceedings of the National Academy of Sciences of the United States of America·L GissmannH zur Hausen
Sep 20, 1995·Journal of the National Cancer Institute·G Y HoS Romney
Dec 1, 1994·American Journal of Clinical Pathology·N ColemanM A Stanley
Aug 1, 1994·The British Journal of Surgery·J H ScholefieldF Sharp
Mar 1, 1996·International Journal of Cancer. Journal International Du Cancer·S K KjaerC J Meijer
Apr 2, 1996·Proceedings of the National Academy of Sciences of the United States of America·J M ArbeitD Hanahan
Mar 1, 1996·European Journal of Obstetrics, Gynecology, and Reproductive Biology·K J Syrjänen
Oct 9, 1996·Biochimica Et Biophysica Acta·H zur Hausen
May 5, 1997·The American Journal of Medicine·L Koutsky
May 5, 1997·The American Journal of Medicine·K R Beutner, A Ferenczy
Jul 29, 1997·International Journal of Cancer. Journal International Du Cancer·M Sugase, T Matsukura
Nov 14, 1997·The New England Journal of Medicine·M FrischM Melbye
Dec 16, 1997·Proceedings of the National Academy of Sciences of the United States of America·K SuzueR A Young
Jan 24, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R M Alani, K Münger
Feb 12, 1998·The New England Journal of Medicine·G Y HoR D Burk
Mar 21, 1998·Proceedings of the National Academy of Sciences of the United States of America·H L GreenstoneJ T Schiller
Apr 1, 1998·Nature·J Banchereau, R M Steinman
Apr 3, 1998·Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology : Official Publication of the International Retrovirology Association·J M PalefskyT M Darragh
Jul 2, 1998·Obstetrics and Gynecology·J J BaldaufP Meyer
Oct 1, 1998·European Journal of Immunology·I H FrazerR W Tindle
Jun 22, 1999·Current Opinion in Immunology·W R Heath, F R Carbone
Jul 2, 1999·International Journal of Cancer. Journal International Du Cancer·I NindlM Dürst
Oct 26, 1999·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·W J van DrielJ B Trimbos
Feb 19, 2000·Current Opinion in Immunology·B Beutler
May 4, 2000·Journal of the National Cancer Institute·H zur Hausen
Jul 19, 2000·Current Opinion in Immunology·V E Schijns
Feb 13, 2001·Journal of Cellular Physiology·D M Da SilvaW M Kast
Mar 3, 2001·Current Opinion in Immunology·C YeeP D Greenberg
Apr 21, 2001·The Journal of Immunology : Official Journal of the American Association of Immunologists·P LenzJ T Schiller
May 9, 2001·The Journal of Immunology : Official Journal of the American Association of Immunologists·W F ChengT C Wu

❮ Previous
Next ❯

Citations

Mar 21, 2008·Expert Opinion on Biological Therapy·Chien-Fu HungT-C Wu
Aug 27, 2005·Expert Opinion on Biological Therapy·George CoukosT-C Wu
Mar 28, 2008·Immunological Reviews·Chien-Fu HungRichard Roden
Jul 26, 2005·Journal of the American College of Surgeons·Diane C Bodurka
Jan 1, 2011·Cancers·Anne-Sophie BergotDeepak Mittal

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.